Doxorubicin News and Research RSS Feed - Doxorubicin News and Research

Doxorubicin hydrochloride is approved for use with other drugs as adjuvant therapy for breast cancer that has spread to the lymph nodes, including cancer that is HER-2 positive or has spread after surgery.

In addition to the uses that have been approved by the FDA, doxorubicin hydrochloride is sometimes used alone or with other drugs to treat other types of cancer. The drug continues to be studied in the treatment of many types of cancer.
Exercise may have added benefit for cancer patients undergoing chemotherapy: Study

Exercise may have added benefit for cancer patients undergoing chemotherapy: Study

Study after study has proven it true: exercise is good for you. But new research from University of Pennsylvania scientists suggests that exercise may have an added benefit for cancer patients undergoing chemotherapy. [More]
Study could lead to improvements in outcomes for women with triple-negative breast cancer

Study could lead to improvements in outcomes for women with triple-negative breast cancer

William M. Sikov, a medical oncologist in the Breast Health Center and associate director for clinical research in the Program in Women's Oncology at Women & Infants Hospital of Rhode Island, served as study chair and lead author for a recently-published major national study that could lead to improvements in outcomes for women with triple-negative breast cancer, an aggressive form of the disease that disproportionately affects younger women. [More]
VentiRx's motolimod receives FDA Fast Track designation for ovarian cancer treatment

VentiRx's motolimod receives FDA Fast Track designation for ovarian cancer treatment

VentiRx Pharmaceuticals, Inc., a clinical stage biopharmaceutical company committed to the development and commercialization of novel Toll-like receptor 8 (TLR8) immunotherapies, today announced that the U.S. Food and Drug Administration (FDA) has granted Fast Track designation to the investigation of motolimod (VTX-2337) when administered in combination with pegylated liposomal doxorubicin (PLD) for the treatment of women with ovarian cancer whose disease has progressed on or recurred after platinum-based chemotherapy. [More]
Versatile nanoparticles offer wide variety of diagnostic and therapeutic applications

Versatile nanoparticles offer wide variety of diagnostic and therapeutic applications

Kit Lam and colleagues from UC Davis and other institutions have created dynamic nanoparticles (NPs) that could provide an arsenal of applications to diagnose and treat cancer. [More]
Celsion announces financial results for second quarter ended 2014

Celsion announces financial results for second quarter ended 2014

Celsion Corporation, an oncology drug development company, today announced financial results for the second quarter ended June 30, 2014. [More]
Aeterna Zentaris signs strategic co-promotion services agreement with ASCEND

Aeterna Zentaris signs strategic co-promotion services agreement with ASCEND

Aeterna Zentaris Inc. today announced a strategic co-promotion services agreement with ASCEND Therapeutics US, LLC. [More]
Encapsula releases 2 new liposome based products

Encapsula releases 2 new liposome based products

Encapsula NanoSciences announces the release of two new liposome ­based products; Curcusome® and Taurosome™. Curcusome® or liposomal curcumin is a nutraceutical supplement that comes innovatively packaged in a powder ­release cap for consumer ease. [More]
Johnson & Johnson sales increase 9.1% to $19.5 billion in second quarter 2014

Johnson & Johnson sales increase 9.1% to $19.5 billion in second quarter 2014

Johnson & Johnson today announced sales of $19.5 billion for the second quarter of 2014, an increase of 9.1% as compared to the second quarter of 2013. Operational results increased 9.4% and the negative impact of currency was 0.3%. [More]
Janssen seeks expanded approval of VELCADE from EU for Mantle Cell Lymphoma

Janssen seeks expanded approval of VELCADE from EU for Mantle Cell Lymphoma

Janssen-Cilag International NV today announced its submission of a type II variation to the European Medicines Agency to expand the label for VELCADE (bortezomib) to include its use, in combination with rituximab, cyclophosphamide, doxorubicin and prednisone, for the treatment of adult patients with previously untreated Mantle Cell Lymphoma (MCL). [More]
EnGeneIC plans for Phase 2a trial of EGFR-targeted doxorubicin-packaged EDV nanocells for GBM

EnGeneIC plans for Phase 2a trial of EGFR-targeted doxorubicin-packaged EDV nanocells for GBM

EnGeneIC, Ltd., an emerging biopharmaceutical company focused on revolutionizing the treatment of cancer through the targeted delivery of therapeutic agents directly to cancer cells, today announced plans to move forward with a Phase 2a clinical trial in the U.S. using its formulation of EGFR-targeted, EDV nanocells packaged with doxorubicin for the treatment of recurrent glioblastoma (GBM), a common and aggressive type of brain tumor. [More]
Celsion acquires all assets of EGEN

Celsion acquires all assets of EGEN

Celsion Corporation, an oncology drug development company, today announced the completion of the acquisition by Celsion of substantially all of the assets of EGEN, Inc., a privately-held biopharmaceutical company focused on the development of nucleic acid-based therapeutics for the treatment of cancer and other difficult to treat diseases. [More]
New treatment for ovarian cancer can improve response rates

New treatment for ovarian cancer can improve response rates

Doctors at the University of Arizona Cancer Center at St. Joseph's Hospital and Medical Center in Phoenix reported today in Lancet Oncology that a new treatment for ovarian cancer can improve response rates (increase the rate of tumor shrinkage) and prolong the time until cancers recur. [More]
Celsion signs definitive asset purchase agreement to acquire EGEN

Celsion signs definitive asset purchase agreement to acquire EGEN

Celsion Corporation (Celsion) (NASDAQ: CLSN), an oncology drug development company, and EGEN, Inc. (EGEN), a privately-held biopharmaceutical company focused on the development of nucleic acid-based therapeutics for the treatment of cancer and other difficult to treat diseases, today announced the signing of a definitive asset purchase agreement in which Celsion will acquire substantially all of the assets of EGEN, including its Phase Ib DNA-based immunotherapy product candidate EGEN-001 and its therapeutic platform technologies, TheraPlas™ for delivery of DNA and mRNA, TheraSilence™ for delivery of RNA, and RAST™ for Cell Enabled Expression and Secretion of RNA. [More]
Genetic changes can predict which patient will benefit from chemotherapy before bladder cancer surgery

Genetic changes can predict which patient will benefit from chemotherapy before bladder cancer surgery

Three genetic changes can predict whether a patient will benefit from chemotherapy before surgery to remove bladder cancer, according to new findings presented by Fox Chase Cancer Center researchers during the 50th Annual Meeting of the American Society of Clinical Oncology. [More]
Study highlights impact of diet, exercise on prevention, treatment and survivorship of cancer

Study highlights impact of diet, exercise on prevention, treatment and survivorship of cancer

This Special Issue titled "The role of diet, body composition, and physical activity on cancer prevention, treatment, and survivorship" comprises both invited reviews and original papers investigating various themes such as the role of omega-3 fatty acids, amino acids, cancer cachexia, muscle health, exercise training, adiposity and body composition. [More]
New nanoscale structures capable of introducing "cocktail" of multiple drugs into cancer cells

New nanoscale structures capable of introducing "cocktail" of multiple drugs into cancer cells

Biomedical engineering researchers have developed daisy-shaped, nanoscale structures that are made predominantly of anti-cancer drugs and are capable of introducing a "cocktail" of multiple drugs into cancer cells. [More]
CytRx announces Phase 2b clinical trial results of aldoxorubicin in subjects with metastatic STS

CytRx announces Phase 2b clinical trial results of aldoxorubicin in subjects with metastatic STS

CytRx Corporation, a biopharmaceutical research and development company specializing in oncology, today announced updated results from its ongoing multicenter, randomized, open-label global Phase 2b clinical trial investigating the efficacy and safety of aldoxorubicin compared with doxorubicin as first-line therapy in subjects with metastatic, locally advanced or unresectable soft tissue sarcomas. [More]
New understanding of toxicity levels of chemotherapy regimens used for early stage breast cancer

New understanding of toxicity levels of chemotherapy regimens used for early stage breast cancer

Oncologists now have a new understanding of the toxicity levels of specific chemotherapy regimens used for women with early stage breast cancer, according to research from The University of Texas MD Anderson Cancer Center. [More]
Anti-cancer drug delivery method smuggles drug into cancer cell before triggering release

Anti-cancer drug delivery method smuggles drug into cancer cell before triggering release

Biomedical engineering researchers have developed an anti-cancer drug delivery method that essentially smuggles the drug into a cancer cell before triggering its release. [More]
IMPAKT breast cancer conference abstracts online

IMPAKT breast cancer conference abstracts online

Xenografts and mathematical modelling; liquid biopsy; nanotechnology; next generation genomics- Science is running fast and the impact of new technologies in the care of patients with breast cancer will be at the core of the sixth edition of the IMPAKT conference on translational research in breast cancer. [More]